Fox J L, Hsu P H, Legator M S, Morrison L E, Seelig S A
Clin Chem. 1995 Nov;41(11):1554-9.
We review several aspects of fluorescence in situ hybridization (FISH) technology that demonstrate its breadth and power in detecting and monitoring genetic abnormalities associated with cancers. The clinical utility of FISH in disease management is demonstrated in several examples, including trisomy 8 detection with high specificity and sensitivity in patients with myeloid leukemias; trisomy 12 detection with higher efficiency than conventional cytogenetics in patients with chronic lymphocytic leukemia; assessment of engraftment success, chimerism, and relapse in opposite sex bone marrow transplantation; and correlation of trisomy 7 with survival time in patients with prostate tumors. Advances in FISH technology include multicolor analyses, which permit the simultaneous detection of several genetic abnormalities by using cohybridization of probes labeled with several fluorescent labels or label combinations, and comparative genomic hybridization, a relatively new method whereby a single hybridization can reveal aberrations across the entire genome.
我们回顾了荧光原位杂交（FISH）技术的几个方面，这些方面展示了其在检测和监测与癌症相关的基因异常方面的广度和能力。FISH在疾病管理中的临床应用在几个例子中得到了证明，包括在髓系白血病患者中以高特异性和敏感性检测8号染色体三体；在慢性淋巴细胞白血病患者中检测12号染色体三体，其效率高于传统细胞遗传学；评估异性骨髓移植中的植入成功、嵌合体和复发情况；以及前列腺肿瘤患者中7号染色体三体与生存时间的相关性。FISH技术的进展包括多色分析，它允许通过使用标记有几种荧光标记或标记组合的探针共杂交同时检测几种基因异常，以及比较基因组杂交，这是一种相对较新的方法，通过一次杂交可以揭示整个基因组的畸变。
